Dec 12 (Reuters) – The European Medicines Agency’s committee on Friday recommended extending the use of Eli Lilly’s blockbuster drug Mounjaro for the treatment of type 2 diabetes in adolescents and children aged 10 years and above.
Treatment options for children with type 2 diabetes for controlling blood sugar are limited to metformin, insulin and Danish rival Novo Nordisk’s older GLP-1 drug, Victoza.
Friday’s extension included the use of Mounjaro as a standalone treatment when metformin is considered inappropriate due to intolerance or contraindications, the committee said.
In a late-stage trial, Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber and Sahal Muhammed)
Comments